“Flexible Dosing of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Initial Results From the Real-World–Simulating Expanded Access Protocol Study, JADE REAL”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 6, Nov. 2025, p. s618, https://doi.org/10.25251/t4rkzz84.